Key result
This review highlights the worse prognosis of concomitant diabetes mellitus and heart failure and summarizes the emerging role of SGLT2 inhibitors and mineralocorticoid receptor antagonists in management.
Why the study?
Concomitant diabetes mellitus and heart failure is frequent and confers worse prognosis, making diabetes management critical for preventing heart failure.
This review highlights the critical intersection of diabetes and heart failure, emphasizing the emerging role of SGLT2 inhibitors and MRAs in improving patient outcomes.
Emphasizes integrated DM-HF care in practice; leaves open optimal prevention strategies for this high-risk group.
The coexistence of diabetes mellitus (DM) and heart failure (HF) is frequent and is associated with a higher risk of hospitalization for HF and all-cause and cardiovascular mortality. It has been estimated that millions of people are affected by HF and DM, and the prevalence of both conditions has increased over time. Concomitant HF and diabetes confer a worse prognosis than each alone; therefore, managing DM care is critical for preventing HF. This article reviews the prevalence of HF and diabetes and the correlated prognosis as well as provides a basic understanding of diabetic cardiomyopathy, including its pathophysiology, focusing on the relationship between DM and HF with a preserved ejection fraction and summarizes the potential aldosterone and the mineralocorticoid receptor antagonists approaches for managing heart failure and DM. Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) are an emerging class of glucose-lowering drugs, and the role of SGLT2Is in DM patients with HF was reviewed to establish updated and comprehensive concepts for improving optimal medical care in clinical practice.
No takes yet. Share an insight, caveat, or question.
Siao et al. (2022) conducted a review in Diabetes Mellitus and Heart Failure. SGLT2 inhibitors and mineralocorticoid receptor antagonists was evaluated. This review highlights the worse prognosis of concomitant diabetes mellitus and heart failure and summarizes the emerging role of SGLT2 inhibitors and mineralocorticoid receptor antagonists in management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: